UNSPSC 51434953: Methyclothiazide/reserpine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434953 Methyclothiazide/reserpine is a Commodity code covering prescription and over-the-counter pharmaceutical products supplied to state and local government health agencies, fire rescue services, and employee health benefit programs. State and local governments buy under this code to stock emergency medications, support pharmacy benefit programs, and maintain pharmaceutical inventories for public health delivery. Recent solicitations show that procurement spans both emergency response medications for fire rescue operations and broader pharmaceutical supply agreements through cooperative purchasing arrangements that serve multiple state and local jurisdictions.

Issuing bodies include city purchasing departments, state health and human services agencies, and multistate cooperative purchasing alliances. The City of Tampa's Purchasing Department solicited advanced life support medications (Solicitation 26P00188, IFB, due April 8, 2026) for Tampa Fire Rescue, specifying four medication line items with a $40,000 estimated contract value and a 5 percent bid discount for Small Local Business Enterprise participation. The Texas Health and Human Services Commission issued an RFI (HHS0017013, due April 3, 2026) exploring direct-to-manufacturer prescription programs as a market intelligence phase ahead of formal solicitation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities including Oregon, requiring vendors to maintain contracts with authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards. Activity appears concentrated in Texas, Minnesota, and Florida, with MMCAP's multistate model suggesting broader regional reach across participating jurisdictions.